EQS-Adhoc: aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier

aap Implantate AG ("aap" or "Company") proposes to the creditors of the mandatory convertible bond 2023/2028 (ISIN: DE000A351ZH9 / WKN: A351ZH) traded on the open market of the Frankfurt Stock Exchange to resolve on an amendment to the terms and conditions of the bond by way of a vote without a meeting of bondholders. The amendment to the terms and conditions of the bond is intended to enable bondholders to exercise their conversion rights without further waiting.

The bond terms and conditions currently stipulate that bondholders can only exercise their conversion right (i.e. the optional conversion) from October 17, 2024. This deadline is to be eliminated without replacement by the amendments to the bond terms and conditions. In order to grant the bondholders the opportunity to elect conversion as early as possible, a period of fourteen days before May 31, 2024 for the first exercise of the conversion right is also to be provided for in the bond terms and conditions .

Bondholders may cast their votes in accordance with the formalities set out in the invitation to vote without a meeting in the period from Tuesday, March 26, 2024, to Thursday, March 28. The corresponding invitation to vote without a meeting is expected to be published on March 8, 2024 in the Federal Gazette and on the company's website under "Investors/Convertible Bond" (aap.de/investors/convertible-bond).

--------------------------------------------------------------

aap Implantate AG share (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges -

Mandatory convertible bond 2023/2028 of aap Implantate AG (ISIN DE0005066609) - Regulated Unofficial Market

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. In addition to the innovative LOQTEQ® anatomical plate system, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. Sales are conducted both through distribution agents and through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.
 

Forward-looking statements

This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Member of the Management Board; Lorenzweg 5; 12099 Berlin

Tel.: 030/750 19 - 170; Fax: 030/750 19 - 290; E-mail: [email protected]